SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 29, 2018--
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage
biotechnology company focused on discovering and developing innovative
immuno-oncology protein therapeutics, will join the Pancreatic
Cancer Action Network (PanCAN) PurpleStride
San Francisco on Sunday, June 3, in memory of Five Prime employee
Melinda Van Roey, who passed away after her battle against pancreatic
PurpleStride San Francisco, the walk to end pancreatic cancer, is one of
55 PurpleStride events across the country, bringing together survivors,
families, researchers and caregivers dedicated to changing the future of
pancreatic cancer. PurpleStride is PanCAN’s most powerful vehicle for
disease awareness and fundraising efforts.
“There is a tremendous unmet need for patients with pancreatic cancer,”
said Aron Knickerbocker, chief executive officer of Five Prime. “As we
continue to advance therapeutic programs targeting this disease, we want
to demonstrate our commitment to patients by supporting PanCAN’s efforts
in the community. I am proud that our employees are devoted to making an
impact on the lives of patients facing pancreatic cancer.”
Pancreatic cancer is the third leading cause of cancer-related death in
the United States with a five-year survival rate of just 9
percent. In 2018, it is predicted that about 55,000 people in the US
will be diagnosed with pancreatic cancer and about 44,000 people will
die from this disease.
With those patients in mind, Five Prime employees and their families
have united to support PanCAN’s urgent mission to save lives and double
survival by 2020. The Company is also supporting the walk as a Bronze
To learn more about PanCAN, visit pancan.org.
About the Pancreatic Cancer Action Network (PanCAN)
The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting
the world’s toughest cancer. In our urgent mission to save lives, we
attack pancreatic cancer on all fronts: research, clinical initiatives,
patient services and advocacy. Our effort is amplified by a nationwide
network of grassroots support. We are determined to improve patient
outcomes today and to double survival by 2020.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc. discovers and develops innovative
therapeutics to improve the lives of patients with serious diseases.
Five Prime's comprehensive discovery platform, which encompasses
virtually every medically relevant extracellular protein, positions it
to explore pathways in cancer, inflammation and their intersection in
immuno-oncology, an area with significant therapeutic potential and the
focus of the company's R&D activities. Five Prime has entered into
strategic collaborations with leading global pharmaceutical companies
and has promising product candidates in clinical and late preclinical
development. For more information, please visit www.fiveprime.com
or follow us on LinkedIn, Twitter and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180529006059/en/
Source: Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc.
Heather Rowe, 415-365-5737
Director, Investor Relations and Corporate Communications